The technology is a new platform that aims to administer CAR T therapy using a two-step approach. In the first step, a peptide is administered to the patient to increase the patient's resident T cells. The second step is administration of a viral CAR construct, which is inserted directly into the lymph nodes of the patient.

The viral construct infects the activated T cells and forms CAR T cells in vivo in the patient. Successful implementation of the therapy may lead to an off-the-shelf product with no need to isolate and expand patient T cells ex vivo, the company said.

Development of the technology will take place at the Mayo Clinic. Mustang plans to file an investigational new drug application for a multicenter phase I clinical trial once a lead construct has been identified.

Financial details of the partnership were not disclosed.

Tetherex licenses adenovirus vaccine platform from Mayo Clinic
Tetherex Pharmaceuticals has obtained an exclusive worldwide license for the development and commercialization of a novel single-cycle adenovirus vaccine...

Minaris to manufacture Mustang Bio's lentiviral gene therapy in Europe
Minaris Regenerative Medicine has signed an agreement with Mustang Bio to enable technology transfer and good manufacturing practice clinical manufacturing...